Company Overview
Snapshot
Founded in January 2009 by Erez Golan and Eyal Kolka, Pi-Cardia operates with 51–200 employees. The company has raised $37 million across 5 funding rounds from 9 investors.
Business overview
Pi-Cardia is a medical device company focused on developing a low-profile catheter for the treatment of aortic stenosis. Its proprietary technology delivers mechanical impact to fracture valve calcifications without damaging surrounding soft tissue. This treatment aims to increase the valve's effective orifice area, offering a non-implant-based solution to eliminate the need for valve replacement. The company operates within the Health Tech & Life Sciences sector, specifically targeting the Medical Devices and Medical Treatment & Therapeutics categories.
Strategic signal
In July 2022, Pi-Cardia received FDA IDE approval for a pivotal study involving its ShortCut™ device. This regulatory milestone is a significant validation of the company's technology and signals a critical step towards broader market access and commercialization for its non-implant-based aortic stenosis treatment.
Log in to access full profile ›Company Intelligence Q&A
- What is Pi-Cardia's core technology?
- Pi-Cardia develops a proprietary low-profile catheter system designed to treat aortic stenosis by delivering mechanical impact to fracture valve calcifications without injuring the surrounding soft tissue, aiming to increase the valve's effective orifice area.
- When did Pi-Cardia receive FDA IDE approval for its ShortCut™ device?
- In July 2022, Pi-Cardia received FDA IDE approval for a pivotal study with its ShortCut™ device, marking a key regulatory advancement for the company.
- When did Pi-Cardia initiate its first-in-human study for aortic stenosis treatment?
- In May 2018, Pi-Cardia initiated its first-in-human study for the novel non-implant-based treatment of aortic stenosis.
- Has Pi-Cardia formed any strategic partnerships?
- In July 2020, Pi-Cardia teamed with China's Venus Medtech, indicating a strategic collaboration in the heart valve market.